A new research report published in the Journal of Leukocyte Biology shows how the bacteria known for causing gum disease–Porphyromonas gingivalis–manipulates the body’s immune system to disable normal processes that would otherwise destroy it. Specifically, the report shows that this pathogen prompts the production of the anti-inflammatory molecule Interleukin-10 (IL-10). This, in turn, inhibits the function of T-cells, which would otherwise help to protect the host from this particular microbial infection.
“Since greater than 50 percent of the U.S. population over 50 years-of-age develop adult periodontal disease, we hope that the results of our study will ultimately help in the development of novel treatments that could prevent or ameliorate the chronic infection caused by the pathogen P. gingivalis,'” said Jannet Katz, D.D.S., Ph.D., a researcher involved in the work from the Department of Pediatric Dentistry at the University of Alabama in Birmingham.
To make this discovery, scientists used cells from mice that were exposed to P. gingivalis. One portion of the cells was treated with an inhibiting antibody against IL-10 and the other portion of cells was not treated. All of the cells were then tested for interferon gamma production. An increase of interferon gamma production was seen in the treated cells, but no increase was found in the untreated cells. These findings suggest that the damage done by P. gingivalis happens when the immune cells of the host are first exposed to this pathogen, and further implies that for treatment to be successful, it must be started as early as possible. This study highlights the mechanism by whichP. gingivalis can establish a chronic infection in the form of periodontal disease and provides insight into how the disease develops. Results also demonstrate the importance of very early intervention either by eradication of the bacterium with specifically designed therapeutics or by prevention via the development of an effective vaccine.